| |
| |
|
| Insider
Information: |
Hastings Paul J |
| Relationship: |
|
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
258,381 |
|
|
Indirect Shares
|
6,636 |
|
|
| Direct
Value |
$270,534 |
|
|
|
Indirect Value
|
$24,819 |
|
|
| Total
Shares |
265,017 |
|
|
| Total
Value |
$295,352 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
5
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -131.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Novelion Therapeutics Inc |
NVLN |
President & CEO, Direc... |
2005-04-29 |
9,500 |
|
0 |
Premium* |
|
|
Pacira Pharmaceuticals, Inc. |
PCRX |
Director |
2023-06-14 |
8,374 |
2013-05-15 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2014-06-19 |
0 |
Premium* |
|
|
Protara Therapeutics, Inc |
TARA |
Director |
|
0 |
2016-10-18 |
6,636 |
Premium* |
|
|
Nkarta, Inc. |
NKTX |
|
2024-03-04 |
240,507 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2024-03-04 |
4 |
D |
$13.33 |
$1,834,768 |
D/D |
(137,642) |
240,507 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
400,204 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2023-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
64,500 |
316,797 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
41,900 |
260,961 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2022-09-28 |
4 |
AS |
$13.03 |
$304,615 |
D/D |
(23,376) |
250,959 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2022-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
19,500 |
280,461 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2021-03-30 |
4 |
AS |
$30.23 |
$522,540 |
D/D |
(17,000) |
236,061 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2024-03-01 |
4 |
D |
$13.00 |
$160,654 |
D/D |
(12,358) |
378,149 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2024-01-16 |
4 |
S |
$8.74 |
$84,752 |
D/D |
(9,697) |
390,507 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2021-06-21 |
4 |
AS |
$26.39 |
$226,219 |
D/D |
(8,500) |
227,561 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2021-09-29 |
4 |
AS |
$26.53 |
$231,051 |
D/D |
(8,500) |
219,061 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2023-05-15 |
4 |
OE |
$29.90 |
$209,300 |
D/D |
7,000 |
14,179 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2023-05-15 |
4 |
AS |
$41.85 |
$292,950 |
D/D |
(7,000) |
7,179 |
0 |
% |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2022-09-21 |
4 |
AS |
$13.01 |
$79,717 |
D/D |
(6,126) |
274,335 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
6,881 |
0 |
- |
|
| NKTX |
Nkarta, Inc. |
Chief Executive Officer |
• • – |
2023-01-17 |
4 |
S |
$5.49 |
$20,264 |
D/D |
(3,691) |
313,106 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2015-08-17 |
4 |
OE |
$10.81 |
$32,430 |
D/D |
3,000 |
5,853 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2015-08-17 |
4 |
AS |
$60.02 |
$180,060 |
D/D |
(3,000) |
2,853 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2015-11-20 |
4 |
OE |
$10.81 |
$32,430 |
D/D |
3,000 |
5,853 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2015-11-20 |
4 |
AS |
$60.00 |
$180,000 |
D/D |
(3,000) |
2,853 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2016-02-17 |
4 |
AS |
$60.00 |
$180,000 |
D/D |
(3,000) |
2,853 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2016-02-17 |
4 |
OE |
$10.81 |
$38,770 |
D/D |
3,000 |
5,853 |
0 |
- |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2021-03-05 |
4 |
S |
$65.88 |
$197,640 |
D/D |
(3,000) |
6,116 |
0 |
% |
|
| PCRX |
Pacira Pharmaceuticals, I... |
Director |
– • – |
2021-03-05 |
4 |
OE |
$13.98 |
$41,940 |
D/D |
3,000 |
9,116 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2014-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,712 |
2,712 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
